Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Trastuzumab emtansine & Breast Cancer / Mammacarcinoma (HER2+)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Trastuzumab emtansine (T‑DM1, Kadcyla TM) is approved by both the FDA and EMA for Breast Cancer / Mammacarcinoma (HER2+). These approvals cover metastatic/advanced disease and, more recently, certain early‑stage/adjuvant settings (1, 2, 3, 4)

References:

(1) Shen et al. 2016 Sci Rep 6: 23262
(2) Peddi & Hurvitz 2013 Future Oncol 9(3): 319-26
(3) Oostra & Macrae 2014 Breast Cancer (Dove Med Press) 6: 103-13
(4) Delgado et al. 2021 ESMO Open 6(2): 100074

…

References (Sources)

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney et al. 2021 JCO 39: 2375–2385
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
Oostra & Macrae 2014 Breast Cancer (Dove Med Press) 6: 103-13
Review
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis
Shen et al. 2016 Sci Rep 6: 23262
Meta-Analysis
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
Delgado et al. 2021 ESMO Open 6(2): 100074
Review
Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
Mano 2020 Future Oncology 16: 2595–2609
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow & LoRusso 2018 Future Oncology 14: 589–602
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer
Peddi & Hurvitz 2013 Future Oncol 9(3): 319-26

AI Chat

7/1/2026

Chat with our artificial intelligence: